Related to China’s Biostar, FMMU Collaborate to Take Skin Disease Drug Through Trials for Military

• PPD Acquires BioDuro to Further Expand Its Outsourcing Capabilities in China
  
• Merck Serono to Invest More than €150M in R&D Center in China
  
• Gilead and GlaxoSmithKline Divvy Up Commercialization of Viread® for HBV in Key Asian Countries
  
• Good and Bad News at Idera
  
• Sinovac Expands Vaccine Capabilities with New JV
  
• Bayer Schering Pharma Receives Chinese Approval for MS Drug and Signs Anticancer Deal with Micromet
  
• Cambridge University and Chi-Med to Study Angiogenesis Effects of Chinese Medicinal Plants
  
• Elusys Wins $143M Contract to Develop an Anthrax Treatment
  
• Meda In-Licenses Commercial Rights to EpiCept’s AML Therapy for $3M
  
• KaloBios Obtains $35M Up Front from Sanofi Pasteur for Clinical Antibody Candidate against Pseudomonas Aeruginosa
  
• GlobeImmune Raises $17.5M in Series E Financing
  
• Halozyme and BioAtla Marry Expertise for the Discovery of New Biologics
  
• Llama Antibodies Used to Detect Botulinum Neurotoxins in Liquids
  
• Optimer Reports Positive Phase III Data for Antibiotic against C. Difficile
  
• Tulane Scores $15M to Bolster Research on Lassa Fever
  
• LFB Licenses Thallion’s Early-Stage Candidate for Treating STEC Infections
  
• SIGA Wins $2.8M DoD Contract to Progress Antiviral into the Clinic
  
• Beijing Pioneer to Provide Olink’s Duolink Product Line in China
  
• ICON and Tigermed Team Up to Facilitate Access to Chinese Patient Populations
  
• AiCuris Raises €55M to Continue Phase II Trials of Cytomegalovirus Drug Candidate